CN110548032A - Application of pyrazolopyrimidine compound in preparation of drugs for preventing/treating tumors - Google Patents

Abstract

The invention provides the application of the compound 1, or the solvate thereof, or the crystal thereof, or the salt thereof in preparing the drugs for preventing and/or treating tumors, and also provides the application of the compound 1, or the solvate thereof, or the crystal thereof, or the salt thereof in preparing mesoporous materials, drug delivery systems, drug carriers and artificial channels

Description

Application of pyrazolopyrimidine compound in preparation of drugs for preventing/treating tumors

Technical Field

The invention belongs to medicine synthesis, and particularly relates to application of a pyrazolopyrimidine compound in preparing a medicine for preventing/treating tumors.

Background

lung cancer is the most serious malignant tumor with the highest morbidity and mortality in the world, and poses great threat to human health. Lung cancer is subdivided into two types according to the biological characteristics of the tumor, clinical treatment and prognosis: small Cell Lung Cancer (SCLC) and Non-small cell lung cancer (Non-small-cell lung cancer, NSCLC). NSCLC is the most common lung cancer and is associated with increased epithelial cell production, accounting for approximately 85% to 90% of lung cancer cases. Non-small cell lung cancer is further divided into several subtypes, which are: lung adenocarcinoma, squamous cell carcinoma of the lung (SCC) and Large Cell Lung Carcinoma (LCLC). Adenocarcinoma or lung adenocarcinoma has a distinct histological feature, with changes in histiocytes, subatomic structure, and composition, accompanied by changes in organs, bronchi, and mucus. Lung adenocarcinoma accounts for approximately 40% of all primary lung cancers. The growth and spread of malignant cells in lung adenocarcinoma is much slower than other subtypes of lung cancer and therefore more detectable than other types of lung cancer. SCC usually occurs in one of the left or right bronchi, and smoking is the leading cause of this type of lung cancer. The clinical manifestations of SCC are generally dyspnea, chest pain and bloody sputum. SCC accounts for approximately 25-30% of primary lung cancers. LCLCs are heterogeneous aggregates of undifferentiated threatening tumors that do not have the cytomorphological characteristics of small cell lung cancer, lung adenocarcinoma and lung squamous carcinoma nor produce mucus. LCLCs often originate in the central epithelial cells of the lung and spread to distant organs. Many studies have shown a close association between LCLC and smoking, accounting for approximately 5-10% of all lung cancers.

In recent decades, with the rapid development of precise medicine, targeted therapy is used for clinical treatment of lung cancer, and a significant effect is achieved, but drug resistance mutation of targeted therapy and partial mutant genes without corresponding targeted drugs are a problem which is difficult to solve in current clinical treatment.

In addition, as a substance with pharmacological activity, like other substances, in the process of crystallization, due to the influence of different physicochemical conditions, intramolecular or intermolecular bonding modes are changed, so that the arrangement mode of molecules or atoms in a lattice space is changed, and different crystal structures are formed, that is, the same substance has two or more spatial arrangements and unit cell parameters, and the phenomenon of existence of the different crystal structures is called polymorphism (polymorphism). Different crystal forms exhibit different melting points and solubilities for the same drug, thereby affecting the bioavailability of the drug and the subsequent formulation process. The dissolution rate of crystals with different shapes can be different, and the molecular groups of the exposed surfaces of different crystals are different, so that the drug effect can be different. Therefore, the crystal of the drug has an influence on the bioavailability, stability, dosage form selection, and therapeutic effect of the drug.

Solvates refer to crystalline substances formed by the molecules of a compound in combination with one or more solvent molecules, which are a ubiquitous form of the compound. The solvate belongs to a polycrystalline type, and plays an important role in the fields of medicines, macromolecules, energy sources and the like. Particularly in the medical field and of great importance, when drugs are combined with solvents to form solvates, the properties exhibited are very different from those exhibited by non-solvates. For example: the molecules will vary in volume, density, refractive index, hygroscopicity, solubility, and the like. Where the solubility of different solvates or non-solvates of a drug varies widely, there may be a large difference in its bioavailability. If the crystal of the medicine is not well controlled in the preparation or storage process, the medicine can not achieve the treatment effect due to the reduction of bioavailability, or the medicine is poisoned due to excessive dosage, thereby causing medical accidents.

Therefore, the development of effective low-toxicity lung cancer therapeutic drugs with novel structures and the study and mastery of different crystals and properties thereof are urgent needs of current clinical medication.

disclosure of Invention

the invention aims to provide application of pyrazolo [3,4-d ] pyrimidine derivatives in preparation of drugs for preventing and/or treating tumors, mesoporous materials, drug delivery systems, drug carriers and artificial channels.

The invention provides an application of compound 1, or a solvate thereof, or a crystal thereof, or a salt thereof in preparing a medicament for preventing and/or treating tumors;

compound 1 has the structure

Further, the tumor is lung cancer.

Further, the tumor is non-small cell lung cancer.

Further, the tumor is lung adenocarcinoma.

furthermore, the medicine can inhibit the proliferation, growth and migration of tumor cells and induce the apoptosis of the tumor cells.

furthermore, the medicine can regulate the protein level of Cyclin E1 in tumor cells, regulate the expression of Bcl-2 and Bax, regulate the activity of caspase and regulate the expression of AMPK-mTOR pathway protein.

preferably, the medicament can reduce the protein level of Cyclin E1 in tumor cells, increase the ratio of Bax/Bcl-2 expression and improve the activity of cleared-Caspase-9 and cleared-Caspase-3.

Further, the medicine can promote the generation of active oxygen in tumor cells.

further, the drug is capable of inducing autophagic death of the tumor cell.

The invention also provides the application of the compound 1, or a solvate thereof, or a crystal thereof, or a salt thereof in preparing mesoporous materials, drug delivery systems, drug carriers and artificial channels;

Compound 1 has the structure

Further, the solvate is a hydrate of compound 1.

Further, the preparation method of the crystal comprises the following steps: adding the compound 1 into a mixed solution of methanol and water, dissolving, filtering, taking liquid, and crystallizing to obtain crystals;

Preferably, in the mixed solution of methanol and water, the volume ratio of methanol to water is 10: 1; the mass volume ratio of the mixed solution of the compound 1, methanol and water is 25 mg: 8 mL; the dissolving mode is heating and dissolving at 60 ℃ until the solution is clear and transparent; the filtration is hot filtration; the crystallization mode is standing crystallization at room temperature, and the crystallization time is 10-30 days, preferably 10 days or 30 days.

In the present invention, "C-H … pi function" means a non-bond weak interaction between a C-H bond and a pi system, the non-bond weak interaction means a generic term for various bonds other than a covalent bond, an ionic bond and a metallic bond, and the pi system means a system capable of forming a conjugated pi bond.

"N-H … N hydrogen bonding" refers to hydrogen bonding between an N-H bond and an N atom.

"O-H … N hydrogen bonding" refers to hydrogen bonding between an O-H bond and an N atom.

"non-porous three-dimensional cross-linked structure" refers to a highly cross-linked spatial structure of non-porous gaps formed by bonding of compound crystal molecules by chemical bonds.

the "porous three-dimensional network structure" refers to a highly cross-linked spatial structure having pore-like gaps formed by bonding crystal molecules of a compound through chemical bonds.

"enantiomers" refers to stereoisomers that are true to mirror images of one another and do not overlap.

"mesoporous material" refers to a class of porous materials with pore sizes between 2-50 nm.

"Drug Delivery Systems" or Drug Delivery Systems (DDS) refer to various forms or formulations of administration of various therapeutic drugs used in the course of preventing and treating diseases, including injections, tablets, capsules, patches, aerosols, suppositories, osmotic pumps, transdermal patches, Drug strips, implants, mucoadhesives, and the like.

"drug carrier" refers to a system that can alter the way and distribution of drugs into the body, control the rate of release of drugs, and deliver drugs to targeted organs.

"Artificial channel" refers to a synthetic channel with similar function as a natural aquaporin.

"solvate" refers to a crystalline substance formed by the combination of a molecule of a compound and one or more molecules of a solvent, which is a ubiquitous form of the compound. In the production of drugs, there are many processes in which a solvent is necessary, and in these processes, the compound comes into close contact with the solvent and, under certain conditions, the corresponding solvate is formed.

"hydrate" is a kind of solvate, and refers to a crystal substance formed by the compound molecules and water molecules together in a certain combination form.

Experiments prove that the compound 1 prepared by the invention has high-activity anti-lung cancer effect, can obviously inhibit the growth of A549 cells, has the inhibiting effect even better than that of a positive control medicament, and has good prospect in preparing medicaments for preventing and/or treating tumors. In addition, the compound 1 also has good thermal stability, obvious layered structure and rather high porosity, and the structure has good application potential in the fields of preparing mesoporous materials, medicine carrying materials and artificial channel materials.

obviously, many modifications, substitutions, and variations are possible in light of the above teachings of the invention, without departing from the basic technical spirit of the invention, as defined by the following claims.

The present invention will be described in further detail with reference to the following examples. This should not be understood as limiting the scope of the above-described subject matter of the present invention to the following examples. All the technologies realized based on the above contents of the present invention belong to the scope of the present invention.

Drawings

FIG. 1: compound 1 has inhibitory effect on a549 cell proliferation.

FIG. 2: visual morphology of a549 cells after treatment with different concentrations of compound 1.

FIG. 3: compound 1 effect on a549 cell cycle-flow diagram.

FIG. 4: immunoblot analysis of a549 cells G1 protein (72 h).

FIG. 5: the Transwell experiment examined the effect of compound 1 on the migration of a549 cells.

FIG. 6: compound 1 at different concentrations inhibited a549 cell migration P < 0.05.

FIG. 7: effect of compound 1 on a549 apoptosis-flow diagram.

FIG. 8: effect of compound 1 on ROS production in a549 cells.

Figure 9a) effect of compound 1 on expression of Bcl-2 and Bax in a549 cells, b) Bax/Bcl-2 expression ratio after treatment of a549 cells with compound 1P < 0.05P < 0.01P < 0.001.

FIG. 10: effect of compound 1 on Caspase family protein in a549 cells.

FIG. 11: effect of compound 1 on a549 cells AMPK-mTOR signaling pathway protein.

FIG. 12: a) effect of compound 1 on a549 cell autophagy pathway proteins LC3I and LC3 II; b) compound 1 acted on a549 cell autophagy pathway protein LC3II/LC3I at a ratio P <0.05, P <0.01, P < 0.001.

FIG. 13: the molecular conformation of crystal 1, crystal atom numbering and overlay (a) conformation 1-a1 and atom numbering (left) and enantiomer 1-a 2; (b)1-A1 and 1-A2 overlay front (left) and top (right) views, where different colors represent different atoms: carbon atom, grey; oxygen atom, red; nitrogen atom, blue; hydrogen atom, white.

FIG. 14: molecular packing diagram and hydrogen bonding network diagram of crystal 1 (hydrogen bonding is indicated by dotted line, and H atoms not forming hydrogen bonding are deleted for clarity); a) molecular packing diagram along the a-axis; b) an analytic graph of a crystal hydrogen bond network along the a direction; c) an analytic graph of hydrogen bonding network along direction b; d) analytic graph of hydrogen bonding network along direction c.

FIG. 15: a) a view of one four-membered ring formed by water and the molecule of compound 1 and the hydrogen bond chain; b) Intermolecular interactions of two adjacent four-membered rings with one-dimensional water chains in the center (host molecules are represented by sticks pattern, guest molecules water by ball and stick pattern); c) a one-dimensional water chain four-membered ring filing schematic diagram is arranged at the center; d) perspective view of a four-membered ring with a water sub-array.

FIG. 16: the crystal 1 has a stacking mode between layers (molecules are represented by space filling mode).

FIG. 17: a) a dnorm surface map elevation of the Hirshfeld surface analysis of crystal 1; b) dnorm surface map back view (white represents forces equivalent to the distance between van der waals forces atoms; red indicates a strong force shorter than the van der waals force distance; blue indicates a weak force longer than van der waals), and c) a 2D fingerprint; d) dnorm surface map of specific intermolecular interaction forces.

FIG. 18: the molecular conformation, crystal atom number and overlay of crystal 2 (a) conformation 2-a1 and atom number (left) and enantiomer 2-a 2; (b) conformation 2-B1 atomic number and enantiomer 2-B2; c)2-A1 and 2-A2 overlay; d)1-A1,2-A1, and 2-B1 (green for 1-A1, yellow for 2-B1, magenta for 2-B1); e)2-B1 and 2-B2.

FIG. 19: a) a four-membered ring and a hydrogen bond chain formed by the compound 1; b) a four-membered ring-like structure; c) the adjacent quaternary ring structures interact with the quasi-quaternary ring structures; d) FIG. c shows the space filling pattern (wherein red is a four-membered ring and green is a four-membered ring).

FIG. 20: crystal 2 a) 2 cross-layer views along the crystallographic b-axis direction; b) FIG. a) space filing pattern; c) C-H … pi enlarged view of four-membered and four-membered like rings between crossing layers; d) the C-H … pi between the cross-layer quaternary rings is enlarged.

FIG. 21: crystal 2 a) relationship of two cross-layer views along the c-axis b) space filing pattern of fig. a).

FIG. 22: hirshfeld surface analysis and 2D fingerprint pattern of Crystal 2.

FIG. 23: the contact among atoms in the crystal of the compound 1 accounts for the proportion of the Hirshfeld surface.

FIG. 24: thermal analysis results for compound 1: a) DSC profile for compound 1; b) TGA profile of compound 1.

FIG. 25: supramolecular morphology of Compound 1 in solution (upper left 1mg/mL normal field, lower left 1mg/mL magnified view; upper right 2mg/mL normal field, lower right 2mg/mL magnified view).

Detailed Description

the raw materials and equipment used in the invention are known products and are obtained by purchasing commercial products.

1. Experimental reagent and equipment

The sources of the experimental reagents for the following examples are shown in table 1:

table 1: experimental reagent

the main experimental equipment and analytical test equipment used in the examples section below are shown in table 2:

Table 2: chemical experiment instrument equipment

2. Synthesis method

example 1 Synthesis of Compound 1 of the present invention

(1) Synthesis of 5-amino-4-cyano-1-tert-butyl-1H-pyrazole (12):

Tert-butylhydrazine 11(0.72g, 8.19mmol) and triethylamine (1.70mL, 12.29mmol) were added to a 50mL round-bottomed flask containing 20mL anhydrous ethanol at room temperature, and then ethoxymethylenemalononitrile 10(1.00g, 8.19mmol) was slowly added dropwise thereto. The reaction mixture was heated at 78 ℃ for 3 hours. The reaction solution was then cooled to room temperature and spin dried to give a viscous orange solid. Water (30mL) was then added thereto with CH₂Cl₂The reaction was extracted (3X 60 mL). The combined organic phases were dried over anhydrous sodium sulfate, and then the solvent was evaporated under reduced pressure and concentrated. A fast curing orange-yellow gum was obtained. The residue was partitioned with 10% EtOAc in hexane (60mL) and the mixture was sonicated. The resulting crystalline solid was filtered, washed with copious amounts of 10% EtOAc in hexane and dried to yield finally light orange crystalline 5-amino-4-cyano-1-tert-butyl-1H-pyrazole 1.29 g, 96.3% yield.¹H NMR(600MHz,DMSO-d₆)δ7.45(s,1H),6.22 (s,2H),1.50(s,9H)。¹³C NMR(150M,DMSO-d₆)δ150.71,138.01, 115.24,74.55,57.76,28.23。

(2) Synthesis of 4-amino-1-tert-butyl-1H-pyrazolo [3,4-d ] pyrimidine (13):

5-amino-4-cyano-1-tert-butyl-1H-pyrazole 12 (1) under nitrogen00g, 6.09mm ol) and formamide (15ml) were heated at 190 ℃ for 6 hours. By CH₂Cl₂(3X 60ml) and H₂The mixture was O (30 ml). The combined organic layers were then dried over anhydrous sodium sulfate and evaporated in vacuo. Passing through silica gel column chromatography (elution: 0% -50% CH)₂Cl₂/CH₃OH) to yield product 13 as a white solid 1.16g with a yield of 55.8%.¹H NMR(6 00MHz,DMSO-d₆)δ8.14(s,1H),8.03(s,1H),7.58(s,2H),1.69(s, 9H)。¹³C NMR(150M,DMSO-d₆)δ158.16,154.72,152.72,130.04,1 01.43,59.23,28.78。

(3) synthesis of 4-amino-3-bromo-1-tert-butyl-1H-pyrazolo [3,4-d ] pyrimidine (14):

N-bromosuccinimide (1.37g, 7.85mmol) was added to a solution containing 4-amino-1-tert-butyl-1H-pyrazolo [3,4-d ] at room temperature]Pyrimidine (1.00g, 5.23mmol) in 100mL acetonitrile. The reaction mixture was then stirred at 80 ℃ for 4 hours. Cooling the reaction mixture to room temperature by using CH₂Cl₂(3X 60mL) and H₂O (30mL), the organic extracts were combined and dried over anhydrous sodium sulfate, and the solvent was evaporated under reduced pressure. Followed by gradient elution through silica gel chromatography (eluent: CH)₂Cl₂) The residue was purified and the desired fractions were combined and evaporated in vacuo to give the desired product as a yellow solid, 0.91g, 64.8% yield.¹H NMR(600M, DMSO-d₆)δ8.20(s,1H),1.67(s,9H)。¹³C NMR(150M,DMSO-d₆)δ 157.51,155.64,153.52,115.29,100.46,60.61,28.61。

(4) Synthesis of 3- (4-amino-1- (tert-butyl) -1H-pyrazolo [3,4-d ] pyrimidin-3-yl) phenol (1):

3-Hydroxyphenylboronic acid pinacol ester (0.40g, 1.79mmol) and the previous reactionThe obtained 4-amino-3-bromo-1-tert-butyl-1H-pyrazolo [3,4-d]Pyrimidine 13(0.40g, 1.49mmol) is dissolved in 1,4-dioxane/H₂O (4: 1,25mL) solvent in a 100mL round bottom flask. Sequentially adding K at room temperature₂CO₃(0.41g, 2.98mmol) and PdCl₂dppf (0.11g, 0.15mm ol) and the reaction mixture was stirred at 100 ℃ for 8 h. The reaction was then cooled and evaporated in vacuo and the residue was attached to silica gel using dichloromethane as solvent. Purifying by silica gel column chromatography (elution: 0% -1% CH)₂Cl₂:CH₃OH) and the desired fractions were evaporated in vacuo to give the desired final product (compound 1)0.30g as a grey solid in 71.1% yield.¹H NMR(600M,DMS O-d₆)δ9.69(s,1H),8.23(s,1H),7.35-7.32(t,J＝8.1Hz,1H),7.06-7.05 (d,J＝7.2Hz,2H),6.87-6.86(dd,J＝8.2Hz,1H),1.74(s,9H)。¹³C N MR(150M DMSO-d₆)δ158.12,154.59,153.77,141,69,134.48,130.2 2,118.93,115.62,115.03,98.55,59.62,28.75。HRMS-ESI(m/z)calcd f or[M+H]⁺,284.1433；found,284.1505。

Example 2 preparation of Crystal 1 and Crystal 2 of Compound 1 of the present invention

(1) Compound single crystals were grown according to standard recrystallization procedures. The method specifically comprises the following steps: compound 1(25mg) prepared in example 1 was dissolved in 8ml of methanol: water (10: 1). After stirring, the mixture was heated to saturation at 60 ℃ until clear and transparent. The hot solution was filtered in time with a syringe filter. The solvent was then slowly evaporated at room temperature. Yellow granular crystals 1 were obtained on day 30.

(2) Using the same method and the same solvent as in step (1), 30 days were changed to 10 days, and yellow granular crystals, i.e., crystals 2 of compound 1, were obtained.

The beneficial effects of the compounds of the present invention are demonstrated by the following experimental examples.

Experimental example 1 evaluation of antitumor Activity of Compound of the present invention

First, experiment method

1. Experimental reagent and instrument

The main reagents used in the following experimental examples are shown in table 3:

Table 3: experimental reagent

the main experimental equipment used in the following experimental examples is shown in table 4:

Table 4: experimental instrument equipment

2. Experimental methods

preparation of solution

(1) preparation of Compound 1 solution

28mg of the compound 1 powder prepared in example 1 was weighed, dissolved in 1mL of dimethyl sulfoxide (DMSO) to prepare a 100. mu.M drug solution, filtered through a 0.22. mu.M sterile microporous membrane, dispensed, and stored in a refrigerator at-20 ℃ in the dark. The samples were diluted to the desired concentration with RPMI-1640 medium before the experiment.

(2) RPMI-1640 complete culture preparation

Preparing RPMI-1640+ 10% FBS + 1% PS culture medium: 5ml FBS (serum) +0.5ml PS (diabody) +44.5ml RPMI-1640, stored in a refrigerator at 4 ℃.

(3) Preparation of MTT solution

weighing 0.5g of tetramethylazodicarbonyl blue (MTT) powder, fully dissolving in PBS solution, and adjusting the final concentration to 5mg/mL^-1filtered by a 0.22 mu M sterile microporous filter membrane, and stored at 4 ℃ in the dark.

(4) Preparation of electrophoresis buffer solution

93.85g of Glycine, 15.15g of Tris and 5g of SDS are weighed to be fully dissolved in 700m L double distilled water, and then the double distilled water is added to be constant volume to 1000mL, and the solution is diluted by 5 times by the double distilled water when in use.

(5) Preparation method of 10 xTBS solution

Weighing 24.2g of Tris alkali and 80g of NaCl, adjusting the pH value to 7.6 by using dilute hydrochloric acid, and fixing the volume to 1L by using double distilled water.

(6) Preparation method of 1 XTSST solution

0.5mL of Tween-20, 100mL of 10 × TBS and 900mL of double distilled water were mixed well and stored at room temperature

(7) Preparation of 5% skimmed milk powder as sealing liquid

5g of skimmed milk powder is weighed and dissolved in 100mL of TBST, and the mixture is stirred to be fully dissolved, namely 5 percent of TBST solution of skimmed milk powder (W/V).

(8) Preparation of BCA solution

Weighing 5g BSA in 100mL TBST fully dissolved, 5% BSA (W/V) TBST solution.

2..2 cell resuscitation

(1) Heating the constant temperature water bath tank to 37 deg.C, wiping the tabletop of the clean bench with 75% alcohol, and starting ultraviolet lamp to irradiate for 30 min;

(2) Preparing 15ml of RPMI-1640 complete culture medium, and adding the RPMI-1640 complete culture medium into a 15ml centrifuge tube;

(3) Taking the A549 cell cryopreservation tube out of liquid nitrogen, immediately placing the tube in a water bath at 37 ℃, quickly and slightly shaking the tube, and unfreezing the cells;

(4) gently blowing and stirring uniformly, and slowly dripping the suspension into a 15ml centrifugal tube containing complete culture medium by using a suction tube;

(5) centrifuging at 20 deg.C and 1000rpm for 3min, and removing supernatant;

(6) adding 1ml of prepared RPMI-1640 complete medium into a centrifuge tube to resuspend cells, transferring the suspension to 25cm of medium added with 4ml²Shaking and uniformly mixing the mixture in a cell culture bottle by a cross method;

(7) Place the flask in 5% CO₂And culturing at 37 ℃ in an incubator.

2.3 cell passages

(1) Washing hands with soap before entering a sterile room, and wiping hands with 75% alcohol to sterilize;

(2) observing cell morphology under an inverted microscope, determining whether the A549 cells are passaged and the dilution times of the cells, and preheating a culture medium, pancreatin and the like at 37 ℃; (3) wiping the table top of the super clean workbench by 75% alcohol;

(4) Opening an ultraviolet lamp of the superclean bench to irradiate the bench surface for about 20min, closing the ultraviolet lamp, and opening a fan to clean air and remove ozone;

(5) Sucking out the old culture medium in the culture bottle by using a pipette, and washing out the residual culture medium by using 2-3ml Hanks liquid as appropriate or washing with a small amount of pancreatin;

(6) Adding 1mL of trypsin-EDTA solution into the culture bottle, shaking uniformly, spreading flatly to fully cover the bottom of the bottle, and placing the bottle in a constant-temperature incubator for digestion for 1 min;

(7) observing under an inverted microscope, turning over the culture bottle immediately when the cell retracts to enable the protrusion to become round, separating the cell from pancreatin, and then pouring off the pancreatin;

(8) Adding a small amount of fresh culture medium containing serum to terminate digestion, repeatedly blowing and beating the digested cells to remove the walls and disperse, centrifuging at 1000rpm for 5min, and removing the supernatant;

(9) Adding a certain amount of fresh culture medium containing serum according to the number of the transfer flasks to resuspend the cells to prepare cell suspension, and subpackaging the cell suspension into new culture flasks;

(10) the bottle cap is covered and slightly turned after being properly screwed down, so as to be beneficial to CO₂the culture flask was returned to 5% CO₂Incubator at 37 ℃;

(11) a549 cells with good growth are taken for experiments.

2.4 cell cryopreservation

(1) Replacing a complete cell culture medium one day before freezing and collecting A549 cells in a logarithmic growth phase;

(2) Adding RPMI-1640 culture medium, fetal calf serum and 10% dimethyl sulfoxide DMSO into a centrifuge tube, preparing cell freezing solution with the ratio of 7:2:1, and standing at room temperature for later use;

(3) A549 cells are digested by adding a trypsin-EDTA solution, collected into a 15ml centrifugal tube and then centrifuged at 1000rpm for 5 min;

(4) Discarding the supernatant, adding the prepared cell frozen stock solution, and blowing gently until the cells are resuspended;

(5) Subpackaging the cell suspension into cell cryopreservation tubes, wherein each tube is 1-1.5 mL, screwing the tube openings, attaching sealing films, and making cryopreservation records;

(6) And (3) placing the frozen cell storage tube in a liquid nitrogen tank for long-term storage at 4 ℃ for 10min → -20 ℃ for 30min → -80 ℃ for 16-18 h (or overnight).

2.5 cell proliferation inhibition assay (MTT method)

(1) A549 cells in logarithmic growth phase were collected after digestion with 0.25% trypsin, and the cell concentration was adjusted to 1X10⁵cell.mL^-1Cells were seeded in 96-well plates at 100. mu.L per well, while blank control wells were placed at 37 ℃ in 5% CO₂The culture is carried out for 24 hours in an incubator with saturated humidity;

(2) Changing complete culture medium containing different concentrations of compound 1(0, 3.125, 6.25, 12.5, 25, 50 μ M), setting 3 multiple wells per concentration, and continuing culturing for 72 h;

(3) Adding 10 mu L of MTT solution into each hole, and continuously culturing in an incubator for 4 h;

(4) After the supernatant is removed by suction, 100 mu L of DMSO solution is added into each hole, and the mixture is vibrated for 10min at a low speed on a shaking table to ensure that the crystallized product is completely dissolved;

(5) Detecting the absorbance value under 490nm wavelength by an enzyme-labeling instrument, and calculating the cell activity;

(6) the experiment was repeated 3 times and the average was taken.

2.6 cell growth State experiments

(1) collecting A549 cells in logarithmic growth phase, digesting with 0.25% trypsin, collecting cells, and adjusting cell concentration to 2 × 10⁵cell·mL^-1adding the mixture into a 6-hole plate, wherein each hole is added with 2 mL;

(2) Culturing in incubator for 24h, adding compound 1(0, 2.5, 5 μ M) with different concentrations;

(3) Continuously placing the mixture in an incubator for culturing for 72 hours, and observing the growth and morphological change of cells under the action of the compound 1 with each concentration under an inverted microscope.

2.7 cell cycle experiments

(1) A549 cells in logarithmic growth phase are taken and inoculated with 1 × 10 cells per well⁵cell·mL^-1inoculating into 6-well plate, adding 2mL complete culture medium into each well, setting three secondary wells in each group, and standing at 37 deg.C，5％ CO₂the culture is carried out for 24 hours in an incubator with saturated humidity;

(2) Changing complete culture medium containing different concentrations of compound 1(0, 2.5, 5 μ M), and continuing culturing;

(3) After 24h, 48h and 72h of culture, cells are digested by 0.25% trypsin solution, precooled phosphate buffer PBS is added, centrifugation is carried out for 3min at 1000rpm, and the cells are washed twice;

(4) adding 70% ethanol solution drop by drop, and fixing overnight at 4 ℃ in a dark place;

(5) After cell fixation, cells were centrifuged at 2000rpm at 4 ℃ for 5min, the supernatant was discarded, and washed twice with PBS;

(6) Adding 500uL PBS containing 50ug/mL ethidium bromide (PI), 100ug/mL RNase A and 0.2% Triton X-100, and incubating at 37 deg.C in the dark for 30 min;

(7) flow cytometry was used to detect 2 million cells per set of samples, and FlowJo software was used to obtain data and analyze cell cycle distribution.

2.8Transwell cell migration assay

(1) Freezing and thawing Matrigel of BD company at 4 ℃ overnight, and refrigerating a 100-microliter gun head for later use;

(2) Matrigel kept operating on ice after the start of the experiment, 1: 8 dilution, coating the upper surface of the bottom membrane of the Transwell chamber, and placing at 37 ℃ for 30min to polymerize Matrigel into gel. Hydrating the base membrane before use;

(3) After digesting A549 cells with 0.25% trypsin, the culture solution was poured off, washed 2 times with PBS solution, resuspended in serum-free medium containing BSA, and the cell density was adjusted to 5X10⁵/mL；

(4) adding 100 μ L of cell suspension into a Transwell chamber, adding treated A549 cells of compound 1(0, 2.5, 5, 10 μ M) at different concentrations, and setting a blank control group with three multiple wells at each concentration;

(5) Add 600. mu.L of 20% FBS in the 24-well bottom chamber, place at 37 ℃ and 5% CO₂culturing in an incubator;

(6) After culturing for 24h, taking out the Transwell chamber, discarding the culture solution in the hole, washing twice with sterile PBS, fixing with methanol for 30min, and properly air-drying the chamber;

(7) Giemsa staining for 15min, gently rubbing off non-migrated cells on the upper layer with a cotton swab, and washing with PBS for three times;

(8) the cells were observed under a 20 Xinverted microscope at random in five selected fields and photographed.

2.9 apoptosis assay

The apoptosis is detected by Annexin V-FITC/PI double staining method, and the method comprises the following steps:

(1) A549 cells grown logarithmically are counted at 5X10⁵cell·mL^-1

Culturing in 6-well plate;

(2) Changing complete culture medium containing different concentrations of compound 1(0, 2.5, 5 μ M), and culturing for 24h and 48 h;

(3) The cell culture medium was aspirated into 15ml centrifuge tubes, cells were digested with trypsin, washed 3 times with precooled PBS, and cell concentration was adjusted to 1X10⁶cell·mL^-1Centrifuging at 2000rmp for 5min, and sucking away PBS;

(4) Adding 400 μ L of 1X Annexin V binding solution into each group, suspending the cells again, adding 5 μ L of Annexin V-FITC staining solution, mixing, and incubating at room temperature in the dark for 5 min;

(5) Adding 10 mul PI staining solution for detecting on machine

(6) Detecting by using a flow cytometer, detecting 2 ten thousand cells in each group of samples, acquiring data by using Cell Quest software and analyzing the apoptosis condition.

2.10DCFH-DA Probe detection active oxygen experiment

(1) Collecting A549 cells in logarithmic growth phase, digesting with 0.25% trypsin, collecting cells, and adjusting cell concentration to 1 × 10⁵cell·mL^-1adding into 6-hole plate, 2mL per hole, culturing for 24 h;

(2) Adding compound 1 with concentration of 0, 2.5, 5 and 10 μ M respectively, and reacting for 24 hr;

(3) According to the ratio of 1:1000, DCFH-DA concentration is diluted to 10 mu mol.L by serum-free culture solution^-1Standby;

(4) after collecting cells by trypsinization, washing the cells twice by precooled PBS, and resuspending the cells by 1mL of DCFH-DA;

(5) Placing in incubator away from light for 20min, and mixing uniformly every 5min to make probe and cell contact sufficiently;

(6) Washing the cells with serum-free culture solution for three times, and then re-suspending the cells by 1 mL;

(7) The mean fluorescence intensity was measured by flow cytometry.

2.11Western Blot assay for Effect of Compound 1 on apoptosis-related protein expression

2.11.1 extraction of Total cellular protein

(1) A549 cells in logarithmic growth phase are inoculated in a 6-well plate, and the cell concentration is adjusted to be 1x10⁵cell/mL^-1Placing the mixture in an incubator for 24 hours;

(2) Adding compound 1 with concentration of 0, 5, 10 and 20 μ M respectively, and acting for 72 h;

(3) Centrifuging at 1000rmp for 5min after trypsinization, collecting cells, washing twice with precooled PBS, and removing supernatant;

(4) mu.L of cell lysate was added to each group of cells, lysed on ice for 30min, then centrifuged at 12000rpm for 10min at 4 ℃ and the supernatant carefully aspirated, and stored at-20 ℃.

2.11.2BCA assay for protein concentration

(1) Sequentially adding 0, 1,2, 4, 8, 12, 16 and 20uL of BSA standard (0.5mg/mL) into a 96-well culture plate, and then complementing the total volume to 20uL by using precooled PBS;

(2) Diluting a sample to be detected by 20 times, and adding 20 mu L of the sample to be detected into a 96-well plate;

(3) adding 200 uL/hole of BCA working solution, placing in an incubator for culturing for 30min, and cooling to room temperature;

(4) measuring absorbance of each hole at 562nm by using an enzyme-labeling instrument, and using water to be zero;

(5) And drawing a protein standard curve, and calculating the protein concentration of the sample to be detected.

2.11.3SDS-PAGE protein electrophoresis

(1) Separating gel with concentration of 12% (see Table 5)

(2) injecting separation glue between the two glass plates to avoid generating bubbles, injecting the separation glue until the lower edge of the comb is 1cm, and slightly adding double distilled water to carry out water sealing;

(3) The concentration of the concentrated glue is 5% (see table 6)

(4) After the separation gel is poured, standing at room temperature for 30min, slowly pouring out the double distilled water on the upper layer after the separation gel is completely polymerized, and completely sucking the residual double distilled water by using a filter paper strip;

(5) rapidly injecting the concentrated glue to the top of the glass plate, inserting a comb to prevent bubbles from being generated, and standing at room temperature for 30min for later use;

(6) Taking the subpackaged total cell protein or plasma protein, adding 5uL of 5 Xloading buffer solution, performing metal bath at 100 ℃ for 10min to denature the protein, and performing centrifugal loading;

(7) Adding 4 mu L of pre-stained protein marker into the holes at the two sides of the protein sample;

(8) The electrophoresis apparatus is started, the required strips are separated by electrophoresis, and the electrophoresis can be stopped.

table 5: preparation of 12% separation gel (15mL)

Table 6: preparation of 5% concentrated adhesive (4mL)

2.11.4 transfer film

(1) soaking a PVDF membrane with a proper size in methanol for about 30s, then placing the PVDF membrane in distilled water for soaking for 2min, and then transferring the PVDF membrane to an electrotransformation liquid;

(2) making a sandwich of spongy cushion, filter paper, separation gel, PVDF membrane filter paper and spongy cushion, and putting the sandwich into a film transfer groove;

(3) Pouring a transfer buffer solution into the container, and putting the container into a cooling device;

(4) Transferring for 100min under the condition of constant pressure of 60V. After the membrane transfer is finished, the PVDF membrane is taken out, and the positions of the front side and the back side and the standard molecular weight reference protein are marked.

2.11.5 blocking, primary antibody incubation, secondary antibody incubation

(1) Placing the membrane successfully converted into the prepared 5% skimmed milk powder, and placing the skimmed milk powder in a sealing liquid for sealing at room temperature for about 1 h; blocking and then using TBST;

(2) diluting anti-clearance-caspase-9, clearance-caspase-3, Bax and Bcl-2 with 5% skimmed milk powder, incubating overnight at 4 ℃, and using beta-actin antibody as an internal reference;

(3) Washing the membrane with 1 × TBST for 3 times, each time for 5min, diluting the secondary antibody with 5% skimmed milk powder, incubating for 1h at room temperature, and washing the membrane with 1 × TBST for 3 times, each time for 15 min.

2.11.6ECL development

(1) mixing ECL chemiluminescence solution A and B at a ratio of 1:1, mixing, and standing at room temperature for 1 min;

(2) The mixed ECL reagent was applied to a PVDF membrane (1mL/10 cm)²) Reacting at room temperature for 1min, and performing chemiluminescence to obtain a strip;

(3) The gel imaging system takes pictures.

2.12Western Blot analysis of Effect of Compound 1 on AMPK-mTOR pathway protein expression

The specific operation method is the same as 2.11, and the expression of AMPK-mTOR pathway protein is detected.

2.13Western Blot assay for the Effect of Compound 1 on autophagy pathway protein expression

The specific operation method is as 2.11, and the expression of the autophagy pathway protein is detected.

2.14 statistical analysis

Statistical analysis was performed using Graphpad Prism, differences between groups were checked by T test, and results were usedShows, the test result P<a difference of 0.05 is statistically significant.

Second, experimental results

1. MTT method for detecting proliferation inhibition effect of each compound 1 on A549 cells

the compound 1 synthesized in example 1 was used, the cell proliferation inhibition was tested by the MTT method at various concentrations (0, 3.125, 6.25, 12.5, 25, 50 μ M), the cell activity was evaluated by using PP1 as a positive control, and human lung adenocarcinoma a549 cells were selected and subjected to an experiment, and the results of the experiment after 72 hours of the effect are shown in table 7.

Table 7: pyrazolo [3,4-d ] pyrimidine derivatives having A549 cell inhibitory activity

from the experimental results, compared with the positive control, the compound 1 has more obvious inhibition effect on the A549 cells, and the inhibition effect is obviously enhanced along with the increase of the drug concentration (see figure 1), which indicates that the compound 1 is concentration-dependent on the growth and proliferation of the A549 cells.

2. Effect of Compound 1 on the growth status of A549 cells

According to the MTT experiment result, the IC of the compound 1 after the compound 1 acts on A549 cells for 72h₅₀The value is 2.12. mu.M, therefore, the invention selects two concentrations of 2.5 and 5. mu.M to perform the morphological influence experiment. After a 72h exposure of a549 cells to various concentrations of compound 1(0, 2.5 and 5 μ M), they were observed under a 20X inverted microscope.

as a result, as shown in fig. 2, the cells in the control group were closely connected and uniform in size, and exhibited a polygonal morphology of normal a549 cells. With the increase of the concentration of the compound 1, the cells are mutually dispersed and crumpled into a round shape, and a phenotype related to apoptosis is presented, so that the compound 1 is proved to be capable of effectively inhibiting the growth of A549 cells.

3. effect of Compound 1 on A549 cell cycle

The PI staining method is adopted to detect the cell cycle, determine the retardation of the medicament on A549 cells, and further prove the inhibition of the medicament on cell proliferation. The results of 24h, 48h and 72h (table 8, fig. 3) all show that the proportion of the A549 cells in the G0/G1 phase is obviously increased after the treatment of the compound 1 compared with the control group, the proportion of the cells in the G0/G1 phase is also increased along with the increase of the concentration of the medicament, and the corresponding proportion of the cells in the S phase and the G2/M phase is reduced, which indicates that the medicament obviously blocks the cell cycle of the A549 cells in the G0/G1 phase, and the blocking effect is medicament dose-dependent, and all the changes result in the inhibition of cell proliferation. Further analysis of the related protein Cyclin E1 involved in G1 phase regulation revealed a significant decrease in Cyclin E1 protein levels in a549 cells with increasing drug concentration (fig. 4).

TABLE 8 results of Effect of Compound 1 on A549 cell cycle

4. Effect of Compound 1 on A549 cell migration

Through Transwell^TMThe results of cell migration experiments (FIGS. 5 and 6) show that the number of cells passing through the cell membrane is significantly less than that of the control group 24 hours after the A549 cells are treated with the compound 1, and the number of cells shows a dose-dependent decrease with the increase of the drug concentration, and shows a very significant inhibitory effect at 10. mu.M (P)<0.05), indicating that the compound 1 can obviously inhibit the migration capability of A549 cells.

In the experiment, the compound 1 is detected to induce the apoptosis activity of A549 cells by an annexin V-FITC/PI double staining method. The effect of 24h and 48h drugs on apoptosis was determined, respectively. As can be seen from fig. 7 and table 9, after a549 cells were treated with different concentrations of compound 1 for 24h, the number of apoptosis increased with increasing drug concentration, and the ratio increased. Compared with the control group, the apoptosis rate is increased from 2.77% to 6.41% and is in a dose-dependent relationship. When a549 cells were treated with compound 1 for 48h, the cells developed different degrees of apoptosis. When the drug concentration is 2.5 mu M and 5 mu M, the apoptosis rate of A549 cells is 14.86 percent and 21.42 percent respectively, and the proportion is obviously increased compared with the apoptosis rate of 4.85 percent of the control group. And also as the concentration of the drug increases, the apoptosis rate gradually increases. Therefore, it was found that compound 1 significantly induced apoptosis of a549 cells.

table 9: results of Effect of Compound 1 on apoptosis of A549 cells

6. effect of Compound 1 on ROS Activity of A549 cells

In order to investigate the action mechanism of compound 1 on a549 cells, the fluorescence intensity of DCF was measured by flow cytometry using a fluorescent probe DCFH-DA to detect active oxygen, and as a result, as shown in fig. 8, after compound 1 at different concentrations acted on a549 cells for 24 hours, the fluorescence intensity after the addition of the drug tended to increase compared with that of the negative control group NC, and thus, the result showed that compound 1 could promote the production of active oxygen in the cells.

7. Effect of Compound 1 on A549 apoptosis-related protein Bcl-2 family protein

in the experiment, cell apoptosis pathway regulatory proteins Bax and Bcl-2 are detected through a Western Blot experiment. From fig. 9a, it can be seen that the expression level of Bax protein increases significantly with the increase of the compound concentration after the a549 cells are treated with the compound 1 for 72 hours, while the expression level of Bcl-2 protein also increases with the increase of the drug concentration, but from fig. 9b, it can be seen that the ratio of Bax/Bcl-2 expression level in the a549 cells is significantly increased after the drug treatment is added, and the ratio of protein expression level increases with the increase of the drug concentration in a concentration-dependent manner, compared with the control group. When the drug concentration reaches 20 μ M, the expression level of Bax/Bcl-2 is increased by more than 6 times compared with the control group. This result indicates that compound 1 can exert the effect of inducing apoptosis by regulating the expression of Bcl-2 and Bax.

8. Influence of compound 1 on Caspase family protein expression of A549 cells

According to the invention, the expression of Caspase protein is detected by using a Western Blot method, as shown in figure 10, after the A549 cells are treated by the compound 1 for 72 hours, compared with a control group, the expression levels of the sheared Caspase-9 (cleared-Caspase-9) and the sheared Caspase-3 (cleared-Caspase-3) are obviously increased, and the activities of the cleared-Caspase-9 and the cleared-Caspase-3 are also higher along with the increase of the concentration of the compound. This result shows that Compound 1 can induce apoptosis by increasing the activity of Cleaved-Caspase-9 and Cleaved-Caspase se-3 in A549 cells via a dose-dependent pathway.

9. Effect of Compound 1 on A549 cell AMPK-mTOR pathway protein

In the experiment, a Western Blot method is adopted to detect the expression quantity of the AM-PK-mTOR pathway protein, as shown in figure 11a, when the compound 1 is used for treating an A549 cell for 72 hours, the activity of P-AMPK (Thr172) is obviously improved, the activity of the protein P-Raptor positively regulated by AMPK is obviously reduced, and the activities of the downstream proteins P-P70-S6K, P-S6(235/236) and P-S6(240/244) of mTOR are also obviously reduced (as shown in figure 11b), and the results show that the compound 1 inhibits the growth of the tumor cell by regulating the AMPK-mTOR pathway.

10. Effect of Compound 1 on autophagy pathway proteins

The experiment evaluates the autophagy level by detecting the expression ratio of the 2 key proteins LC3II/LC 3I.

As shown in fig. 12a, when a549 cells were treated with the compound for 72h, the expression level of LC3I protein was decreased compared to the control group, while the expression level of LC3II was increased. See fig. 12b, the ratio of LC3II/LC3I increased significantly compared to the control, and as the drug concentration increased, the expression of LC3II/LC3I showed a dose-dependent increase. As can be seen, compound 1 induced autophagic death of a549 cells, thereby causing apoptosis.

Experimental example 2 thermal Properties of Compound 1 of the present invention

The thermal properties of compound 1 prepared in example 1 were characterized by thermogravimetric Analysis (TGA) and Differential Scanning Calorimetry (DSC) in the present invention, the test was performed in air at a temperature of 400 ℃ from room temperature and at a heating rate of 10 ℃ for min^-1。

From the DSC diagram (see fig. 24a) it can be seen that the thermal behavior of the compound mainly comprises 2 processes, an endothermic and an exothermic process. The exothermic period is 132.31-144.03 ℃, the peak temperature is 137.35 ℃, the exothermic amount is 11.70J/g, and the exothermic in the period can be a weak exothermic peak formed in the recrystallization process of the sample. And two endothermic stages, 186.31 ℃ -199.29 ℃ and 198.29 ℃ -206.78 ℃, the peak temperature and the endothermic quantity are 192.43 ℃, 22.11J/g and 202.05 ℃ and 68.74J/g respectively, the two endothermic stages are compound melting stages, and the 2 melting peaks are caused by that the crystal is an alpha crystal. The final endothermic stage is 365.26-371.62 deg.C, peak temperature is 368.33 deg.C, endothermic amount is 269.30J/g, and the stage is compound decomposition stage. The TGA diagram (see fig. 24b) of the compound shows 87.97% weight loss, and the compound decomposes at a relatively high temperature, indicating that the compound structure is relatively stable.

Experimental example 3 Scanning Electron Microscope (SEM) of Compound 1 of the present invention

Compound 1 prepared in example 1 was purified using methanol in a ratio of 10: 1: water was prepared into a 1mg/mL solution and a 2mg/mL solution, respectively, and the supramolecular morphology of the sample was observed by SEM (see FIG. 25).

SEM images of the sample solution at 1mg/mL show that Compound 1 is present in regular micro-disk shapes at this concentration, with good dispersion. And the high-resolution SEM image shows that the surface of the micro-disc is rough and has an obvious layered structure, and the compound is possibly a mesoporous material and can be used for preparing a drug-loaded material. And SEM image of 2mg/mL shows that at this concentration, compound 1 appeared to be significantly agglomerated, the microdisk was connected together, and the layered structure disappeared.

experimental example 4 supramolecular Structure test of Compound of the invention and Crystal

Crystal 1 and crystal 2 of compound 1 obtained in example 2 were examined by X-ray single crystal diffraction method, and the results were as follows:

Parameter C of Crystal 1₁₅H₁₇N₅O,Mr＝584.69g.mol^-1；monoclinic,space g roup P 1 21/n 1；α＝9 0°,β＝90.024(8)°,γ＝90°；Z＝2；calc density＝1.292g·cm^-3；F(0 00)＝620.0；T＝100K；R_int＝0.0781；μ＝0.088mm^-1；miller index ranges ,-7≤h≤7,-11≤k≤13,-29≤l≤29；θ_max＝52.04°,θ_min＝3.36°；T_min＝0.541,T_max＝0.745；11668reflections collected；2952independent reflec tions；Data/restraints/parameters:2952/0/206；Goodness-of-fit on F²＝1.010； R₁＝0.0540；wR₂＝0.1432；R indexes(all data)R₁＝0.0767；wR₂＝0.1561；Lar gest diff.peak/hole/e:and

Structural analysis of crystal 1: the crystal 1 of the compound 1 is a monoclinic crystal, and a P121/n space group crystal. Crystal 1 of the compound only has one mirror image enantiomer, 1-A1 and 1-A2 (as shown in figure 13 a), and is found by a molecular conformation overlay chart, as shown in figure 13b, 2 phenolic groups are relative to a nitrogen-containing heterocyclic parent nucleus pyrazolo [3,4-d ]]The pyrimidines are in a para-cross conformation, 1-A1 and 1-A2 are mirror image molecules which do not overlap with each other, and the corresponding dihedral angle (C5-C7-C10-C15) of 1-A1 is τ₁τ of 1-a2 at 69.050(305) °₂＝-69.050(305)°。

Since compound 1 contains a large number of N atoms and O atoms and is prone to hydrogen bonding (see table 10), the crystal stability of this compound is mainly maintained by hydrogen bonding. These hydrogen bonds allow the compound to form a stable three-dimensional network (see fig. 14 a). In order to fully understand the crystal, the complex hydrogen bond network of crystal 1 was analyzed. Firstly, the analysis is started from the direction of a crystallographic axis, adjacent molecules do not directly interact with each other, and crystals are stacked by a solvent- - -a guest molecule H contained in the crystals₂the O atom in O is used as a H donor to form intermolecular hydrogen bond with phenol O12; pyrimidine exocyclic amino group N6 as hydrogen bond donor with H₂O atoms in O form hydrogen bonds; and C11 atom on phenol ring as donor H and H₂The O atoms in O form hydrogen bonds, these three types of hydrogen bonds, so that adjacent host molecules are connected into a one-dimensional supramolecular chain extending along the crystallographic a-axis direction as shown in fig. 14 b. Next, as shown in FIG. 14c, the molecular interaction along the crystallographic b-axis direction is mainly hydrogen bonding with the N3 atom on the pyrimidine ring of the adjacent molecule by the phenolic group O12 as a hydrogen bonding donor. Finally, the stacking of the molecules in the crystallographic c-axis direction depends on the phasethe two adjacent molecules of pyrimidine exocyclic amino N6 form intermolecular hydrogen bonds with N3 atom in pyrimidine ring as hydrogen bond donors, and C17 on tertiary butyl group as H donor forms C-H-pi interaction with phenol ring (see FIG. 14 d).

Table 10: hydrogen bonding parameter of crystal 1

Symmetry codes:(i)x,-1+y,z(ii)-x,-y,1-z(iii)2-x,1-y,1-z(iv)1-x,-y,1-z

In crystal 1, two conformational enantiomers 1-A1 and 1-A2 of the compound form a closed four-membered ring structure containing 2 solvent water molecules in a cavity in a two-type hydrogen bonding mode (as shown in figure 15a), and a strong hydrogen bonding action is formed between a host molecule and a guest water molecule. For two adjacent four-membered rings, as shown in FIG. 15b, there is no direct interaction between them, but rather, they form intermolecular hydrogen bonds (O2-H2B … O12, O1-H1A … O12, N6-H6A … O2, N6-H6B … O12, C11-H11 … O1, C11-H12 … O2) with the guest water molecules in the nanocavity by using them as bridges, so that a tubular stack is formed along the a-axis direction.

After recognizing the local connection pattern of the molecules, the overall arrangement pattern of the crystal 1 is analyzed. As shown in FIG. 16, in the same layer, layer1 is taken as an example, four-membered rings formed by connecting four molecules 1-A11-A11-A21-A2 by hydrogen bonding form a ladder-like structure similar to type II molecules along the direction of crystallographic b-axis (Leong WL, vitamin JJ. one-dimensional correlation polymers: compatibility and selectivity in structures, properties, and applications. chemical reviews.2010; 111: 688-764). And the molecular steps layer1 and the adjacent molecular steps layer2 are arranged in a parallel stacking manner. Along the crystallographic C-axis direction, adjacent molecular steps layer1 and layer 1' interact with weak intermolecular bonds C-H … π bonds. Thus, the stacking of an infinite number of molecular steps forms a fine three-dimensional network structure.

Hirshfeld surface analysis and 2D fingerprinting of Crystal 1 As shown in FIG. 17, in the dnorm surface map of Crystal 1 (FIGS. 17a, b), the deep red spots are due to intermolecular N-H … N and O-H … N interactions, and the other visible spots on the surface are related to guest and host intermolecular interactions in the crystal. In the 2D fingerprint (fig. 17c), there are two pairs of spikes pointing to the lower left of the plot, typical of N … H and O … H hydrogen bonding, which account for 14.5% and 8.8% of the entire Hirsfeld surface interaction, respectively. In the top left and bottom right corners of the fingerprint map, a characteristic symmetrical "wing" shape appears, which is a C-h. The sharp peaks formed along the diagonal diffusion points in fig. 17c represent H … H interactions, which account for up to 55.5% of the total Hirshfeld surface area. It is shown that the crystal is stabilized mainly by the action of H … H. In contrast, the C … C effect represents only 0.7% of the total surface area of Hirshfeld, indicating that there is little pi-pi stacking effect in crystal 1.

Crystal 2 parameters: c₁₅H₁₇N₅O,Mr＝283.33g.mol^-1；monoclinic；space group P 1 21/n 1；α＝90°,β＝ 113.35(3)°,γ＝90°；Z＝8；calc density＝1.284g·cm^-3； F(000)＝1200.0；T＝173K；R_int＝0.0890；μ＝0.086mm^-1；miller index ranges,-19≤h≤19,-13≤k≤13,-23≤l≤22；θ_max＝52.698°,θ_min＝2.908°； T_min＝0.0674,T_max＝0.745；23885reflections collected；5936independent reflections；Data/restraints/parameters:5936/0/390；Goodness-of-fit on F²＝0.987；R₁＝0.0565；wR₂＝0.1383；R indexes(all data)R₁＝0.1249； wR₂＝0.1746；Largest diff.peak/hole/e:and

The present inventors have found that crystals 2 cultured for 10 days and crystals 1 cultured for 30 days have the same crystal system and space group, but exhibit completely different molecular conformations and crystal arrangements. As shown in fig. 18d, overlapping the host molecules of crystal 1 with the molecules of crystal 2 revealed that the host molecular framework of crystal 1 was completely different from that of crystal 2. And only one pair of enantiomers in crystal 1, while two different conformations, 2-A1 and 2-B2, 2, are present in crystal 2 (see FIGS. 18a, B). As shown in FIGS. 18C and e, 2-A1,2-A2 and 2-B1,2-B2 are mirror image molecules which do not overlap with each other, and the dihedral angle (C5-C7-C10-C15) τ of 2-A1 is correspondingly increased₁τ 2-a2 at 45.620(434) °₂τ -45.620(434) °, 2-B1₃τ of 45.734(445) ° and 2-B2₄＝-45. 734(445)°。

In crystal 2, there are 3 hydrogen bonding modes, forming 2 structural units. The first structural unit is a quaternary ring structure (see FIG. 19a) formed by intermolecular hydrogen bonding between enantiomers (O12-H12 … N3) and hydrogen bonding interactions between the same molecules (N6-H6 … N3) in the same way that a crystalline 1 quaternary ring functions. Different from the crystal 1, the crystal 2 is also provided with a structural unit similar to a four-membered ring (shown in figure 19b), which has only one hydrogen bonding mode, and a hydrogen bond (O12 ' -H12 ' … N3 ') formed by an O atom positioned on a phenol group at the 3-position N of a pyridine ring extends in a b-axis direction in a wireless way. Unlike crystal 1 in terms of structural units, crystal 1 has its quaternary annular cavities occupied by solvent water molecules and adjacent four-membered rings in parallel stacked relationship, while crystal 2 has adjacent four-membered and four-like rings interleaved with each other (see fig. 19c, d) and cavities occupied by each other due to the fact that the molecular twist angle is not used in both crystals.

Table 11: hydrogen bonding parameter of crystal 2

Symmetry codes:(i)x,1+y,z(ii)-x,-y,1-z(iii)x,-1+y,z

The crystal 2 interlayer relationship is shown in figure 20a, b, although there is no direct interaction relationship between the four-membered ring and the four-like ring in the same cross layer, they rely on the interaction between the four-membered ring in the lower layer and the four-like ring in the previous cross layer by two C-H … pi bonds, one C-H … pi bond is shown in figure 20C, the tertiary butyl carbon on the four-membered ring interacts with the pyridine ring in the four-membered ring structure by C-H … pi in parallel arrayis stacked. The other C-H … pi bond is formed by taking C14 of a phenol ring of a four-membered ring between an upper crossed layer and a lower crossed layer as a hydrogen donor and passing a pyridine ring of the other four-membered ring through weak C-H … piInteract (see fig. 20 d). These two C-H … pi effects cause the crystal molecules to extend indefinitely in the direction of the C-axis.

As can be seen from the views 21a, b of crystal 2 along the c-axis of the crystal, crystal 2 is repeatedly stacked with intersecting layers, forming a shape resembling a molecular ladder of type IX (Leong WL, Vital JJ. One-dimensional coordination polymers: complex and diversity in structures, properties, and applications. chemical reviews. 2010; 111: 688-764).

For two crystals of the same compound 1, the presence of two diastereomers (Z '═ 2) in crystal 2 compared to the case where only one diastereomer (Z' ═ 1) is present in crystal 1, indicates that crystal 1 is a thermodynamically controlled crystal product and crystal 2 is a kinetically controlled crystal product.

crystal 2Hirshfeld surface analysis and 2D fingerprinting is shown in fig. 22, and the dark red spots in the dnorm surface plots (22a, b) are the interaction of N on the pyrimidine ring with the exocyclic amino group N and the interaction of N on the pyrimidine ring with the hydroxyl group O of phenol. The 2D fingerprint (fig. 22C) showed a force contribution of 17.5% between N … H, 3.9% between O … H, 16.2% between C … H and a maximum interaction contribution of 61.0% between H … H. It is shown that crystal 2 also maintains the stability of the crystal through the interaction between H … H.

FIG. 23 shows the contribution of various types of intermolecular contacts on the Hirshfeld surface in two crystals of Compound 1. comparison of this figure shows that the interactions between the two crystals are not very different, and all contain the presence of H … H, N … H and O … H hydrogen bonds, the stability of the crystals is maintained mainly by H … H interactions, and almost no π - π interactions are present in the crystals, but there is some difference. The O … H fraction is significantly increased in crystal 1 compared to crystal 2, since crystal 1 is a hydrate and the presence of water provides excess O … H fraction.

In conclusion, the compound 1 prepared by the invention has high-activity anti-lung cancer effect, can obviously inhibit the growth of A549 cells, has the inhibiting effect even better than that of a positive control medicament, and has good prospect in preparing medicaments for preventing and/or treating tumors. In addition, the compound 1 also has good thermal stability, obvious layered structure and rather high porosity, and the structure has good application potential in the fields of preparing mesoporous materials, medicine carrying materials and artificial channel materials.

Claims (11)

1. Use of compound 1, or a solvate thereof, or a crystal thereof, or a salt thereof for the manufacture of a medicament for the prevention and/or treatment of a tumor;

Compound 1 has the structure

2. Use according to claim 1, characterized in that: the tumor is lung cancer.

3. Use according to claim 2, characterized in that: the tumor is non-small cell lung cancer.

4. Use according to claim 3, characterized in that: the tumor is lung adenocarcinoma.

5. Use according to claim 1, characterized in that: the medicine can inhibit proliferation, growth and migration of tumor cells and induce apoptosis of the tumor cells.

6. Use according to claim 1, characterized in that: the medicine can regulate the protein level of Cyclin E1 in tumor cells, regulate the expression of Bcl-2 and Bax, regulate the activity of caspase, and regulate the expression of AMPK-mTOR pathway protein.

preferably, the medicament can reduce the protein level of Cyclin E1 in tumor cells, increase the ratio of Bax/Bcl-2 expression and improve the activity of cleared-Caspase-9 and cleared-Caspase-3.

7. Use according to claim 1, characterized in that: the medicine can promote the generation of active oxygen in tumor cells.

8. Use according to claim 1, characterized in that: the drug is capable of inducing autophagic death of the tumor cell.

9. use of compound 1, or a solvate thereof, or a crystal thereof, or a salt thereof, for the preparation of mesoporous materials, drug delivery systems, drug carriers, artificial channels;

compound 1 has the structure

10. Use according to any one of claims 1 to 9, characterized in that: the solvate is a hydrate of compound 1.

11. Use according to any one of claims 1 to 9, characterized in that: the preparation method of the crystal comprises the following steps: adding the compound 1 into a mixed solution of methanol and water, dissolving, filtering, taking liquid, and crystallizing to obtain crystals;

Preferably, in the mixed solution of methanol and water, the volume ratio of methanol to water is 10: 1; the mass volume ratio of the mixed solution of the compound 1, methanol and water is 25 mg: 8 mL; the dissolving mode is heating and dissolving at 60 ℃ until the solution is clear and transparent; the filtration is hot filtration; the crystallization mode is standing crystallization at room temperature, and the crystallization time is 10-30 days, preferably 10 days or 30 days.